{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Alcohol use disorder",
      "Comorbid",
      "Major depression",
      "Mirtazapine"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "27327217",
  "DateCompleted": {
    "Year": "2017",
    "Month": "11",
    "Day": "21"
  },
  "DateRevised": {
    "Year": "2019",
    "Month": "10",
    "Day": "08"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2016",
        "Month": "06",
        "Day": "15"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1016/j.psychres.2016.06.005",
      "S0165-1781(16)30249-9"
    ],
    "Journal": {
      "ISSN": "1872-7123",
      "JournalIssue": {
        "Volume": "242",
        "PubDate": {
          "Year": "2016",
          "Month": "Aug",
          "Day": "30"
        }
      },
      "Title": "Psychiatry research",
      "ISOAbbreviation": "Psychiatry Res"
    },
    "ArticleTitle": "Mirtazapine in comorbid major depression and an alcohol use disorder: A double-blind placebo-controlled pilot trial.",
    "Pagination": {
      "StartPage": "326",
      "EndPage": "330",
      "MedlinePgn": "326-330"
    },
    "Abstract": {
      "AbstractText": [
        "This was a first double-blind, placebo-controlled pilot study to evaluate the efficacy of the novel antidepressant medication mirtazapine for treating both the depressive symptoms and the level of alcohol consumption of subjects with comorbid major depressive disorder and an alcohol use disorder (MDD/AUD). The results of two previous studies of mirtazapine in MDD/AUD subjects had suggested efficacy for mirtazapine for decreasing their level of depressive symptoms, but level of alcohol consumption had not been assessed in those studies. All subjects in this 12-week pilot study were randomized to either mirtazapine or placebo, and also received motivational enhancement therapy. Between-group analyses involving the outcome measures of depressive symptoms, level of alcohol consumption, and level of alcohol craving indicated no significant differences between groups, possibly because of limited sample size. However, within-group t tests in the mirtazapine group showed a significant decrease in depressive symptoms by week 2, also noted at all subsequent assessments (weeks 3, 4, 6, 8, 10, and 12) during the 12-week study. In contrast, no significant decrease in depressive symptoms was noted in the placebo group until week 8. No evidence of efficacy was found for mirtazapine for decreasing level of alcohol consumption in MDD /AUD subjects."
      ],
      "CopyrightInformation": "Copyright \u00a9 2016 Elsevier Ireland Ltd. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA. Electronic address: corneliusjr@upmc.edu."
          }
        ],
        "LastName": "Cornelius",
        "ForeName": "Jack R",
        "Initials": "JR"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA."
          }
        ],
        "LastName": "Chung",
        "ForeName": "Tammy",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA."
          }
        ],
        "LastName": "Douaihy",
        "ForeName": "Antoine B",
        "Initials": "AB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA."
          }
        ],
        "LastName": "Kirisci",
        "ForeName": "Levent",
        "Initials": "L"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA."
          }
        ],
        "LastName": "Glance",
        "ForeName": "Jody",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA."
          }
        ],
        "LastName": "Kmiec",
        "ForeName": "Julie",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA."
          }
        ],
        "LastName": "FitzGerald",
        "ForeName": "Douglas",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Pittsburgh, Western Psychiatric Institute and Clinic, 3811 O'Hara Street, Pittsburgh, PA 15213, USA."
          }
        ],
        "LastName": "Wesesky",
        "ForeName": "Maribeth A",
        "Initials": "MA"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "University of Miami, Department of Psychiatry, Miller School of Medicine, 1120 NW 14th Street, Miami, FL 33136, USA."
          }
        ],
        "LastName": "Salloum",
        "ForeName": "Ihsan",
        "Initials": "I"
      }
    ],
    "GrantList": [
      {
        "GrantID": "R01 AA013370",
        "Acronym": "AA",
        "Agency": "NIAAA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AA015173",
        "Acronym": "AA",
        "Agency": "NIAAA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R21 AA022123",
        "Acronym": "AA",
        "Agency": "NIAAA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 DA019142",
        "Acronym": "DA",
        "Agency": "NIDA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "K24 AA015320",
        "Acronym": "AA",
        "Agency": "NIAAA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "K02 DA017822",
        "Acronym": "DA",
        "Agency": "NIDA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R01 AA014357",
        "Acronym": "AA",
        "Agency": "NIAAA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "R21 AA022863",
        "Acronym": "AA",
        "Agency": "NIAAA NIH HHS",
        "Country": "United States"
      },
      {
        "GrantID": "P50 DA005605",
        "Acronym": "DA",
        "Agency": "NIDA NIH HHS",
        "Country": "United States"
      }
    ],
    "PublicationTypeList": [
      "Journal Article",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Ireland",
    "MedlineTA": "Psychiatry Res",
    "NlmUniqueID": "7911385",
    "ISSNLinking": "0165-1781"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antidepressive Agents"
    },
    {
      "RegistryNumber": "250PJI13LM",
      "NameOfSubstance": "Mianserin"
    },
    {
      "RegistryNumber": "A051Q2099Q",
      "NameOfSubstance": "Mirtazapine"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "psychology"
      ],
      "DescriptorName": "Alcohol Drinking"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "psychology"
      ],
      "DescriptorName": "Alcohol-Related Disorders"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Antidepressive Agents"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Comorbidity"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "psychology"
      ],
      "DescriptorName": "Depression"
    },
    {
      "QualifierName": [
        "drug therapy",
        "epidemiology",
        "psychology"
      ],
      "DescriptorName": "Depressive Disorder, Major"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [
        "analogs & derivatives",
        "therapeutic use"
      ],
      "DescriptorName": "Mianserin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Mirtazapine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Pilot Projects"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Treatment Outcome"
    }
  ]
}